A Study of Navenibart in Participants With Hereditary Angioedema

Inclusion Criteria:

• Documented diagnosis of HAE (Type 1 or 2). The following must be met:

1. Documented clinical history consistent with HAE

2. Lab findings consistent with HAE Type 1 or 2

• Experienced at least 2 HAE attacks during the Run-In period, as confirmed by aninvestigator based on meeting the protocol-specified definition of an HAE attack.

Exclusion Criteria:

• Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1inhibitor deficiency, HAE with normal C1-INH (also known as HAE type 3), idiopathicangioedema, or angioedema associated with urticaria.

• Use of therapies prescribed for the prevention of HAE attacks may not be used duringthe trial or within the below time frames prior to the Run-In Period (adultparticipants may be on these medications at the time of the Screening Visit, butwill need to washout prior to entering the Run-In Period):

1. Lanadelumab within 90 days prior to Run-In

2. Berotralstat within 21 days prior to Run-In

3. Plasma-derived C1INH for LTP within 14 days prior to Run-In

4. Tranexamic acid, oral danazol, oral stanazolol, and oral oxandrolone within 3days prior to Run-In

5. All other prophylactic therapies, including investigational drugs, requireconsultation with the Medical Monitor